Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (1)

2023

  1. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 4, pp. 1060-1072